Theranib will be attending the BIO International Convention, that is the premier global event for biotechnology and life sciences. Our team will be actively engaging with peers to explore scientific collaborations and strategic partnerships, to advance innovation in oncology. We look…
Theranib’s US Patent Published
Theranib Inc. announces the publication of its US patent on January 9, 2025, securing protection for VE3, a groundbreaking ALDH1A3-targeted cancer therapy.